The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, on March 10, 2026, notified regarding the APIs Imports from China.
The following has been stated namely:-
• The domestic demand for high-dependence APIs is dynamic and driven by the requirements of the formulation industry for both domestic consumption and exports. Installed capacity for these APIs is primarily within the private sector. Since 2020, through various policy interventions such as the Scheme for Promotion of Bulk Drug Parks and the Production Linked Incentive (PLI) Schemes, the Government has facilitated the creation of an ecosystem for domestic manufacturing.
• Under the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) /Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as “PLI Scheme for Bulk Drugs’), domestic manufacturing capacity of approximately 56,800 MT per annum has been established for 28 out of 41 identified critical products. The list of these 28 products is placed at Annexure-II. As of December 2025, 38 greenfield projects covering 28 notified products have been commissioned under the Scheme.
[Press Release ID: 2237414]
